Notice of Results

Theracryf PLC

14 November 2024

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Notice of Interim results and Presentation via Investor Meet Company

Alderley Park, 14 November 2024 - TheraCryf plc (AIM: TCF), formerly Evgen Pharma plc, the clinical stage drug development company focussing on oncology and neuropsychiatry, announces that the Company's unaudited interim results for the six months to 30 September 2024 will be released on Thursday 28 November 2024.

The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the Investor Relations section of the Company's website: www.theracryf.com/investors.

Huw Jones, CEO, and Toni Hänninen, CFO will provide a live presentation via the Investor Meet Company platform at 11am on Thursday 28 November 2024.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 27 November 2024, 09:00 GMT, or at any time during the live presentation. Investors who already follow TheraCryf plc on the Investor Meet Company platform will automatically be invited.

Investors can sign up to Investor Meet Company HERE.

-Ends-

Enquiries

TheraCryf plc Dr Huw Jones, CEO Toni Hänninen, CFO Dr Helen Kuhlman, CBO	[phone] [e-mail]
Cavendish Capital Markets (NOMAD and Broker) Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance) Nigel Birks / Harriet Ward (ECM)	[phone]
Vigo Consulting Rozi Morris	[phone] [e-mail]

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications including glioblastoma* neurodevelopmental disorders, addiction, anxiety and narcolepsy [*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. As well as a number of industry partnerships with companies, including Stalicla SA, in neurodevelopmental disorders. The Company has sourced know how for programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is quoted on AIM in London and trades under the ticker symbol TCF. 

For further information, please visit: www.theracryf.com 

 

END